Treatment of Post-Inflammatory Hypopigmentation on the Face

First-Line Treatment Options

• The British Journal of Dermatology recommends topical calcineurin inhibitors, such as tacrolimus or pimecrolimus, as first-line treatment for post-inflammatory hypopigmentation on the face, with approximately 50% repigmentation over 8 weeks of treatment 1
• Topical calcineurin inhibitors have a better side-effect profile than highly potent topical steroids, making them suitable for facial application 1

Second-Line Treatment Options

• Photodynamic therapy may be considered for treatment-resistant cases, with 70-89% clearance rates for facial lesions 2
• Narrowband UVB therapy can be effective for generalized hypopigmentation, though results may vary based on location and duration of the condition 1
• The combination of topical tacrolimus with Excimer UV radiation appears to enhance repigmentation over UV therapy alone, particularly for UV-sensitive sites like the face 1

Procedural Interventions for Resistant Cases

• Laser therapy may be considered for resistant cases, though there are risks of long-term side effects including persistent erythema and potential for further hypopigmentation 2, 4
• Dermabrasion has shown efficacy in some studies but carries significant risk of long-term side effects including hypopigmentation and should be used cautiously 4

Adjunctive Treatments

• Moisturizers with urea or glycerin should be used concurrently to prevent excessive dryness that may worsen the condition 5

Important Considerations and Cautions

• Physical therapies, such as dermabrasion, chemical peels, and laser, come with significant risk of long-term side effects including hypopigmentation and persistent erythema 4
• Ablative laser techniques carry greater risk than non-ablative techniques and require anti-infective prophylaxis 4

Treatment Algorithm

• The British Journal of Dermatology recommends starting with topical tacrolimus or pimecrolimus for 8-12 weeks 1
• If inadequate response, consider adding narrowband UVB or Excimer laser therapy 1

Monitoring and Follow-up

• Assess response to treatment every 4-8 weeks 1